ArticleJournal of the American Board of Family Medicine : JABFM2026
Prostate Specific Antigen Ordering After Implementation of a Point-of-Care Reminder to Discuss Screening.
Article in Journal of the American Board of Family Medicine : JABFM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Point-of-Care Ultrasound, Prevention and Screening, Family Medicine Workforce, Navigating Systems, and Improving Patient Care.Journal of the American Board of Family Medicine : JABFMArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2018, prostate cancer screening with prostate specific antigen (PSA) received a "C" recommendation from the US Preventive Services Task Force for men aged 55 to 69 years. In January 2023, our health system implemented a point-of-care electronic reminder for primary care clinicians to discuss PSA screening for men aged 55 to 69.
methodsWe assessed the impact of reminder implementation on monthly rates of PSA ordering from January 1, 2022 to July 31, 2024 by performing interrupted time series analyses for men aged 55 to 69 years (for whom the reminder was implemented) and men aged 50 to 54, 70 to 74, and ≥75 years.
resultsBefore reminder implementation, PSA was ordered in a median of 6.4% of visits for men aged 55 to 69 years versus a median of 10.2% of visits after reminder [adjusted incidence rate ratio (aIRR) 1.57 (95% CI: 1.43-1.73)]. The postreminder period was associated with smaller but significantly increased rates of PSA ordering in men aged 50 to 54 [aIRR 1.44 (1.25-1.65)], 70 to 74 [aIRR 1.26 (1.14-1.39)], and ≥75 years [aIRR 1.11 (1.02-1.11)].
conclusionsImplementation of an electonic medical record (EMR) reminder to discuss PSA screening was associated with a large increase in PSA ordering among men in the targeted age-group, but also smaller increases in age groups for whom the balance of benefits and harms of PSA screening may be less favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.